ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    "Acquired angioedema"
Previous Study | Return to List | Next Study

C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00125541
Recruitment Status : Completed
First Posted : August 1, 2005
Last Update Posted : May 4, 2009
Sponsor:
Information provided by:
Sanquin

Brief Summary:

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.


Condition or disease Intervention/treatment Phase
Angioedema Drug: C1 inhibitor concentrate (C1-esteraseremmer-N) Phase 2 Phase 3

Detailed Description:

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema
Study Start Date : November 2006
Actual Primary Completion Date : April 2008
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources


Intervention Details:
    Drug: C1 inhibitor concentrate (C1-esteraseremmer-N)
    every 5-7 days


Primary Outcome Measures :
  1. The primary objective in this clinical study is to evaluate the prevention of angioedema attacks in patients prophylactically treated with C1-esteraseremmer-N. [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. The secondary objective of this study is to evaluate the safety and clinical activity of C1-esteraseremmer-N. [ Time Frame: 16 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Inclusion criteria for hereditary angioedema patients:

  • Established diagnosis of hereditary angioedema type I or II: markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4.
  • Patients already using C1 inhibitor concentrate for prophylaxis of angioedema attacks.
  • Age ≥ 16 years
  • Signed informed consent by patient and patient's legal representative if under 18 years old

Inclusion criteria for acquired angioedema patients:

  • Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4.
  • Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life.
  • Age ≥ 16 years
  • Patient already using C1 inhibitor concentrate for prophylaxis of angioedema attacks
  • Signed informed consent by patient and patient's legal representative if under 18 years old

Exclusion Criteria:

Exclusion criteria for hereditary angioedema patients:

  • Use of angioedema prophylactic medication during the study, other than C1-esteraseremmer-N.
  • Change in oral contraceptives starting from the last two months before the start of the trial until the end of the study period.
  • Presence of clinically relevant C1 inhibitor auto antibodies
  • Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than in part A of this protocol.
  • Usage of heparin starting from the last two days prior to the study until the end of the study period.
  • B-cell malignancy
  • Pregnancy or lactation
  • History of allergic reaction to C1 inhibitor concentrate or other blood products

Exclusion criteria for acquired angioedema patients:

  • Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study
  • Usage of heparin within the last two days prior to the study
  • Pregnancy or lactation
  • History of allergic reaction to C1 inhibitor concentrate or other blood products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00125541


Locations
Netherlands
Academic Medical Centre
Amsterdam, Netherlands, 1100 DD
Sponsors and Collaborators
Sanquin
Investigators
Principal Investigator: M. M. Levi, Prof. Dr. Academic Medical Centre Amsterdam

Responsible Party: P. Strengers, Sanquin
ClinicalTrials.gov Identifier: NCT00125541     History of Changes
Other Study ID Numbers: KB2003.01C
First Posted: August 1, 2005    Key Record Dates
Last Update Posted: May 4, 2009
Last Verified: May 2009

Keywords provided by Sanquin:
MeSH: angioneurotic edema, complement 1 inactivators
Hereditary Angioedema Type I or II, Acquired Angioedema

Additional relevant MeSH terms:
Angioedema
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Complement C1 Inactivator Proteins
Complement Inactivating Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs